MIAC
MIAC is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Seventy-five CASTING participants discontinued because of country-specific early trial closure.
- The Timed 25-Foot Walk Test and Timed Nine-Hole Peg Test were not applicable to participants rolling over from CASTING.
- Eligibility criteria were updated in August 2020 and March 2021.
- The ocrelizumab infusion duration was reduced from 3.5 hours to 2.0 hours in August 2020.
- The safety follow-up was changed to 48 weeks after the last infusion, and additional follow-up until B-cell repletion was removed in March 2021.
These findings describe the trial, not the service provider’s performance or responsibility.
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
- A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
- A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for MIAC?
The 2026-10-09 snapshot links MIAC to 3 distinct CTIS trials. Recorded services include Medical expertise, Expert MRI reading of suspected cases of Progressive Multifocal Leukoencephalopathy (PML) in patients diagnosed with Multiple Sclerosis, Expert MRI Reading of suspected cases of Progressive Multifocal Leukoencephalopathy (PML) in patients diagnosed with Multiple Sclerosis, Imaging Vendor. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for MIAC?
The most frequently recorded therapeutic areas are Neurology, Immunology. Recorded phases include Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to MIAC conducted?
The linked trials record locations in 23 countries, including France, Belgium, Bulgaria, Germany, Denmark. These are trial locations, not confirmed office locations or countries where MIAC delivered services.
What can this page tell me about MIAC's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under MIAC. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- MIAC AG